-
Electronic (PDF)
-
Site License
-
Enterprisewide
Equine Encephalitis - Pipeline Review, H1 2012
Global Markets Direct, January 2012, Pages: 32
Equine Encephalitis – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Equine Encephalitis - Pipeline Review, H1 2012', provides an overview of the Equine Encephalitis therapeutic pipeline. This report provides information on the therapeutic development for Equine Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Equine Encephalitis. 'Equine Encephalitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Equine Encephalitis.
- A review of the Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Equine Encephalitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Equine Encephalitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Equine Encephalitis Therapeutic Products under Development, Key Players in Equine Encephalitis Therapeutics, Equine Encephalitis Pipeline Overview, Equine Encephalitis Pipeline, Equine Encephalitis Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Equine Encephalitis Overview
Therapeutics Development
An Overview of Pipeline Products for Equine Encephalitis
Equine Encephalitis Therapeutics under Development by Companies
Equine Encephalitis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Equine Encephalitis Therapeutics – Products under Development by Companies
Equine Encephalitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Equine Encephalitis Therapeutics Development
CytoGenix, Inc.
AlphaVax, Inc.
Equine Encephalitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DNA Vaccines For Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Equine Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Western Equine Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEE TC-83 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEE C-84 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Equine Encephalitis Therapeutics – Discontinued Products
Equine Encephalitis Therapeutics - Dormant Products
Equine Encephalitis – Product Development Milestones
Featured News & Press Releases
May 08, 2006: CytoGenix And USDA To Collaborate In Developing A synDNA Vaccine Against Costly Livestock Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Equine Encephalitis, H1 2012
Products under Development for Equine Encephalitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
CytoGenix, Inc., H1 2012
AlphaVax, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Equine Encephalitis Therapeutics – Discontinued Products
Equine Encephalitis Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Equine Encephalitis, H1 2012
Products under Development for Equine Encephalitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
